Edition:
United Kingdom

Avadel Pharmaceuticals PLC (AVDL.OQ)

AVDL.OQ on NASDAQ Stock Exchange Global Market

7.93USD
23 Feb 2018
Change (% chg)

$0.07 (+0.89%)
Prev Close
$7.86
Open
$7.86
Day's High
$7.97
Day's Low
$7.80
Volume
32,153
Avg. Vol
61,423
52-wk High
$12.30
52-wk Low
$7.53

Latest Key Developments (Source: Significant Developments)

Avadel Pharma Receives Orphan Drug Designation From FDA For FT 218
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Avadel Pharmaceuticals Plc ::AVADEL PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR FT 218 FOR THE TREATMENT OF NARCOLEPSY.  Full Article

Avadel Pharmaceuticals Issues 2018 Corporate Outlook
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Avadel Pharmaceuticals Plc ::AVADEL PHARMACEUTICALS ISSUES 2018 CORPORATE OUTLOOK.REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE VIEW $0.25 TO $0.35.SEES FY 2018 REVENUE $110 MILLION TO $130 MILLION.SEES FY 2017 REVENUE $165 MILLION TO $175 MILLION.- ‍NDA FILING FOR FT218 EXPECTED BY YEAR-END 2018​.- COMMERCIAL LAUNCH FOR NOCTIVA ON TARGET FOR Q2 2018.FY2017 EARNINGS PER SHARE VIEW $1.48, REVENUE VIEW $171.8 MILLION -- THOMSON REUTERS I/B/E/S.AVADEL PHARMACEUTICALS- AV001 IS EXPECTED TO COMPETE IN AN ESTIMATED MARKET SIZE OF ABOUT $30 - $40 MILLION PER YEAR ONCE LAUNCHED IN 2019.- EXPECTS NEGATIVE CASH FLOW IN 2018.- ‍ASSESSING TAX CUTS AND JOBS ACT OF 2017 AND, ACCORDINGLY, IS UNABLE TO PROVIDE 2018 ADJUSTED DILUTED EPS GUIDANCE​.AVADEL PHARMACEUTICALS - ESTIMATES THAT PEAK REVENUES FOR NOCTIVA COULD BE AS HIGH AS $750 MILLION OR MORE PER YEAR.  Full Article

Flamel technologies announces shareholder approval of cross-border merger
Friday, 12 Aug 2016 

Flamel Technologies Sa : Avadel Pharmaceuticals limited will re-register as irish public limited co and will be known as Avadel Pharmaceuticals Plc . Flamel technologies announces shareholder approval of cross-border merger . Received shareholder approval to reincorporate its country of domicile to Ireland from France via a cross-border merger .Under terms of reincorporation, Flamel will merge with and into its wholly owned subsidiary, Avadel Pharmaceuticals Ltd.  Full Article

Flamel Technologies reports Q2 GAAP loss per share $0.48
Monday, 8 Aug 2016 

Flamel Technologies SA : Total revenue for Q2 2016 was $38.9 million, compared to $48.6 million during same period last year . Q2 adjusted loss per share $0.02 . Q2 GAAP loss per share $0.48 . Has lowered its 2016 research and development spending guidance to range or $30 to $40 million .2016 revenue guidance increased to $125 to $140 million.  Full Article

Janus Capital Management reports 5.3 pct passive stake in Flamel Technologies - SEC filing
Friday, 8 Jul 2016 

Janus Capital Management LLC:Janus Capital Management reports 5.3 percent passive stake in Flamel Technologies as of June 30 versus earlier passive stake of 10.7 percent as of Dec. 31, 2015.  Full Article

Flamel Technologies maintains full year 2016 revenue guidance
Monday, 9 May 2016 

Flamel Technologies SA : Maintaining its full year 2016 revenue guidance . Expects research & development expenses to be in range of $35 - $50 million, up from $25.6 million in 2015 . FY 2016 revenue view $124.6 million -- Thomson Reuters I/B/E/S . Flamel Technologies reports first quarter 2016 results . Q1 adjusted earnings per share $0.04 . Q1 GAAP loss per share $0.15 . Q1 revenue $36.2 million versus I/B/E/S view $34.1 million . Sees FY 2016 revenue $110 million to $130 million .Q1 earnings per share view $0.14 -- Thomson Reuters I/B/E/S.  Full Article

Flamel Technologies SA receives FDA approval of Akovaz
Monday, 2 May 2016 

Flamel Technologies SA:Says FDA has approved company's new drug application for Akovaz.Flamel expects to launch Akovaz during third quarter 2016 in a strength of 50 mg/mL.  Full Article

BRIEF-Avadel Pharmaceuticals Announces Pricing Of $125 Mln 4.50 Pct Exchangeable Senior Notes

* AVADEL PHARMACEUTICALS ANNOUNCES PRICING OF $125.0 MILLION 4.50% EXCHANGEABLE SENIOR NOTES DUE 2023